An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma.

In Focus from the latest issue— An Embarrassment of Riches: Three FDA-Approved #Bispecific Antibodies for Relapsed Refractory #MultipleMyeloma, by @RossFirestone, @szusmani, and Lesokhin. https://t.co/TcAPx7VHXT @MSKCancerCenter #mmsm #immunooncology https

RT @BCD_AACR: In Focus from the November issue— An Embarrassment of Riches: Three FDA-Approved #Bispecific Antibodies for Relapsed Refracto…

In Focus from the November issue— An Embarrassment of Riches: Three FDA-Approved #Bispecific Antibodies for Relapsed Refractory #MultipleMyeloma, by @RossFirestone, @szusmani, and Lesokhin. https://t.co/voCbZbwYQo @MSKCancerCenter #mmsm #immunooncology htt

RT @BCD_AACR: An Embarrassment of Riches: Three FDA-Approved #Bispecific Antibodies for Relapsed Refractory #MultipleMyeloma, by @RossFires…